Intranasal zolmitriptan is effective and well tolerated in acute cluster headache

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN27362692

Enrollment

Registered

2006-02-23

Start date

2003-09-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cluster headache Signs and Symptoms Headache

Interventions

Zolmitriptan nasal spray versus placebo.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cluster headache with attacks longer than 45 minutes.

Exclusion criteria

Exclusion criteria: Contraindications to zolmitriptan in participating countries.

Design outcomes

Primary

Measure	Time frame
Proportion of patients who have taken active drug with headache relief at 30 minutes.	—

Secondary

Measure	Time frame
Pain free at 30 minutes.	—

Countries

Germany, Italy, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026